Literature DB >> 20065015

Should hepatitis B serosurveys methodology be reconsidered?

Jorge Luis Salinas, Martin Rodriguez.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20065015      PMCID: PMC2803529          DOI: 10.4269/ajtmh.2010.09-0488

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


× No keyword cloud information.
Dear Sir: With interest, we read the paper by Pereira and others1 and would like to take this opportunity to comment on the accuracy of hepatitis B serosurveys according to the current knowledge of the biology and natural history of the hepatitis B virus (HBV). Although the presence of HBsAb has classically been thought to preclude the possibility of active HBV infection, studies in recent years have suggested that as many as 10–25% of patients with positive HBsAg also have positive HBsAb.2 Therefore, a methodological approach that assumes that the presence of HBsAb excludes chronic active HBV infection may be inaccurate. Another important issue is the necessity to describe the prevalence and natural history of occult hepatitis B, which is defined as serologically undetectable HBsAg despite the presence of HBV DNA in the serum or liver. This condition has seldom been studied in the general population. One study in an HBsAg-negative Canadian Inuit community found a prevalence of 18% in individuals with anti-HBc antibodies and 8% in HBV-seronegative individuals,3 whereas another study found it in 16% of HBV/hepatitis C virus (HCV)-negative, healthy Korean subjects with normal transaminase values.4 We also have to consider the potential clinical relevance of this situation in the future, because these patients may develop HBV reactivation on chemotherapy or immune suppression, transmit HBV through blood transfusions or organ transplants, or even have increased risk of hepatocelular carcinoma.5 Although laborious and economically challenging, especially in developing countries, it is of palmary importance to address the coexistence of HBsAg and HBsAb and the prevalence of occult infection to have a better idea of the real prevalence and relevance of the hepatitis B virus in areas thought to be of low or moderate endemicity. Jorge Luis Salinas University of Alabama at Birmingham 1530 Third Avenue, South, BDB 327 Birmingham, AL 35294-0012 E-mail: jsalinas@uab.edu Martin Rodriguez University of Alabama at Birmingham 1900 University Boulevard, THT 229 Birmingham, AL 35294-0006 E-mail: mrodri2@uab.edu
  5 in total

1.  Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea.

Authors:  Seong Man Kim; Ki Sung Lee; Chi Jun Park; Ja Young Lee; Kyung Ho Kim; Joon Yong Park; Jin Heon Lee; Hak Yang Kim; Jae Young Yoo; Myoung Kuk Jang
Journal:  J Infect       Date:  2006-03-27       Impact factor: 6.072

2.  Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants.

Authors:  Olivier Lada; Yves Benhamou; Thierry Poynard; Vincent Thibault
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  Occult hepatitis B virus infection in a North American community-based population.

Authors:  Gerald Y Minuk; Dong-Feng Sun; Julia Uhanova; Manna Zhang; Shauna Caouette; Lindsay E Nicolle; Adam Gutkin; Karen Doucette; Bruce Martin; Antonio Giulivi
Journal:  J Hepatol       Date:  2005-01-13       Impact factor: 25.083

Review 4.  [Natural history of chronic hepatitis B virus infection].

Authors:  Herman Vildózola Gonzales; Jorge Luis Salinas
Journal:  Rev Gastroenterol Peru       Date:  2009 Apr-Jun

5.  Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil.

Authors:  Leila M M B Pereira; Celina M T Martelli; Edgar Merchán-Hamann; Ulisses R Montarroyos; Maria C Braga; Maria L C de Lima; Maria R A Cardoso; Marília D Turchi; Marcelo A Costa; Luiz C A de Alencar; Regina C Moreira; Gerusa M Figueiredo; Ricardo A A Ximenes
Journal:  Am J Trop Med Hyg       Date:  2009-08       Impact factor: 2.345

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.